JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

JNJ

168.03

+1.28%↑

NVS

117.07

+0.85%↑

ABT

127.93

+1.35%↑

MDT

92.47

+0.6%↑

ELV.US

288.56

+1%↑

Search

Axsome Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

100.38 0.1

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

99.39

Max

101.15

Pagrindiniai rodikliai

By Trading Economics

Pajamos

15M

-59M

Pardavimai

2.7M

121M

Pelno marža

-48.914

Darbuotojai

712

EBITDA

14M

-57M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+74.55% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-08-04

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-529M

4.9B

Ankstesnė atidarymo kaina

100.28

Ankstesnė uždarymo kaina

100.38

Naujienos nuotaikos

By Acuity

35%

65%

106 / 375 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bearish Evidence

Axsome Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-07-29 23:57; UTC

Įsigijimai, susijungimai, perėmimai

EQT: To Spend Y407.82B for Tender Offer

2025-07-29 23:56; UTC

Įsigijimai, susijungimai, perėmimai

EQT: Tender Offer Price Is Y5,700 a Share

2025-07-29 23:54; UTC

Įsigijimai, susijungimai, perėmimai

EQT To Start Tender Offer for Fujitec

2025-07-29 23:50; UTC

Rinkos pokalbiai

Nikkei May Fall Amid Uncertainty Over Earnings, Domestic Politics -- Market Talk

2025-07-29 23:36; UTC

Rinkos pokalbiai

Gold Steady Ahead of FOMC Decision -- Market Talk

2025-07-29 22:57; UTC

Rinkos pokalbiai

Perseus May Step Up Capital Management at FY 2025 Result -- Market Talk

2025-07-29 22:50; UTC

Rinkos pokalbiai

Mondelez Warns of Price Increases in North America -- Market Talk

2025-07-29 22:44; UTC

Įsigijimai, susijungimai, perėmimai

St Barbara: Potential Divestment of Nova Scotia Ops to be Weighed in 1Q FY26

2025-07-29 22:41; UTC

Įsigijimai, susijungimai, perėmimai

St Barbara FY25 All-in Sustaining Cost A$4,582/Oz

2025-07-29 22:41; UTC

Įsigijimai, susijungimai, perėmimai

St Barbara 4Q All-in Sustaining Cost A$4,613/Oz

2025-07-29 22:35; UTC

Uždarbis

IGO Maintains Nova Life of Mine Production Guidance

2025-07-29 22:35; UTC

Uždarbis

IGO Expects FY 2026 Greenbushes Output of 1.50 Million-1.65 Million Tons

2025-07-29 22:35; UTC

Uždarbis

IGO Expects FY 2026 Greenbushes Cash Costs of A$310-A$360/Ton

2025-07-29 22:34; UTC

Uždarbis

IGO Expects Train 1 of Kwinana Refinery to Be Fully Impaired

2025-07-29 22:34; UTC

Uždarbis

IGO Expects to Impair Kwinana Refinery Assets by A$70 Million-A$90 Million

2025-07-29 22:34; UTC

Rinkos pokalbiai
Uždarbis

Mondelez Snack Demand Holding Up Better in Europe Than U.S. -- Market Talk

2025-07-29 22:33; UTC

Uždarbis

IGO Had A$279.7 Million of Cash at End-June

2025-07-29 22:33; UTC

Uždarbis

IGO 4Q Underlying Free Cash A$2.4 Million

2025-07-29 22:33; UTC

Uždarbis

IGO FY Sales Revenue A$512.5 Million

2025-07-29 22:33; UTC

Uždarbis

IGO 4Q Sales Revenue A$126.9 Million, Up 15% on 3Q

2025-07-29 22:32; UTC

Uždarbis

IGO FY Nickel Production 17,173 Tons

2025-07-29 22:32; UTC

Uždarbis

IGO 4Q Nickel Production 5,107 Tons, Up 22% on 3Q

2025-07-29 22:32; UTC

Uždarbis

IGO 4Q Lithium Hydroxide Production 2,126 Tons, Up 36% on 3Q

2025-07-29 22:31; UTC

Rinkos pokalbiai
Uždarbis

Global Equities Roundup: Market Talk

2025-07-29 22:31; UTC

Rinkos pokalbiai
Uždarbis

Mondelez Sees Consumers Trading Down, Buying in Bulk -- Market Talk

2025-07-29 22:31; UTC

Uždarbis

IGO 4Q Spodumene Cash Cost A$366/Ton, Up 7% on 3Q

2025-07-29 22:31; UTC

Uždarbis

IGO FY Spodumene Production 1.48 Million Tons

2025-07-29 22:30; UTC

Uždarbis

IGO 4Q Spodumene Production 340,000 Tons, Flat on 3Q

2025-07-29 22:30; UTC

Uždarbis

IGO 4Q Underlying Ebitda A$62 Million

2025-07-29 22:22; UTC

Uždarbis

Starbucks Abandons Mobile Order, Pickup-Only Stores -- WSJ

Akcijų palyginimas

Kainos pokytis

Axsome Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

74.55% į viršų

12 mėnesių prognozė

Vidutinis 175.23 USD  74.55%

Aukščiausias 210 USD

Žemiausias 148 USD

Remiantis 16 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Axsome Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

16 ratings

16

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

107.24 / 112.29Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bearish Evidence

Vidutinės trukmės periodas

Neutral Evidence

Ilgalaikis periodas

Strong Bullish Evidence

Rinkos nuotaikos

By Acuity

106 / 375 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.